The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic Adenocarcinoma

The aim of this study is to investigate whether the albumin value and the ratios of biochemical markers; hemoglobin, albumin, lymphocyte and platelet (HALP score) and lymphocyte-C-reactive protein ratio (LCR) can predict the survival and recurrence of the disease in patients with pancreatic adenocarcinoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreatic Neoplasms Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreas Cancer Pancreatic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Whipple operation and total pancreatectomy due to pathologically confirmed pancreatic adenocarcinoma

Exclusion criteria

Patients with other malignant tumors (choledochal tumor, papilla tumor and duodenal tumor)

Treatment and study plan

Primary outcomes

Disease-Free Survival Times

Time frame: 4 Years
HALP Score

Time frame: 4 Years

Hemoglobin x Albumin x Lymphocyte / Platelet
Overall Survival Time

Time frame: 4 Years
LCR Score

Time frame: 4 Years

Lymphocyte / CRP

Sponsors and collaborators

Lead sponsor

Ege University

Other

Registry information

Important dates

Study start: 2017
Primary completion: 2021
Study completion: 2023
First posted: Aug 14, 2024
Registry last updated: Aug 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed